Memorial Health ends gender-affirming surgeries for anyone under 19
SAVANNAH, Ga. (WSAV) — Memorial Health in Savannah is no longer providing gender-affirming surgery for transgender patients under 19.
This is in direct response to an executive order by the Trump administration.
Savannah Pride Center said that they are deeply troubled by this decision, that gender-affirming care is medically necessary for transgender patients.
'We should care because when it happens to our neighbor, it will eventually happen to us,' Bell said.
Memorial Health is the only hospital in the Savannah area that performs gender affirmation surgery under insurance for trans men and women. It's something Bell said is life-saving for many of the people they help.
'This is an opportunity for the city and medical providers and businesses to go beyond pride flags and move into real policy shifts that protect, nurture, and advance our LGBTQ community and other marginalized communities,' Bell said.
Memorial health told News 3 that they have performed some kinds of gender-affirming surgery, but have never had a full gender reassignment program.
They released this statement.
'Memorial Health has never had a gender-affirming surgical program which would require certain standards of care across multiple clinical disciplines. Like other hospitals, we have a responsibility to follow state and federal laws and regulations. For gender-affirming surgeries there are laws and regulations around age. We follow those. Licensed physicians use their training and experience to exercise independent medical judgment to assess patients' needs and determine the course of treatment within those laws and regulations.'
In response to that statement Savannah Pride released this.
'Savannah Pride Center is deeply disappointed in Memorial Health's decision to cancel all scheduled gender-affirming top surgeries and its attempt to obscure this fact when responding to why they made this move. While Memorial Health may not have officially designated a 'gender-affirming surgical program,' the reality is that licensed surgeons have been safely performing top surgeries for adult transgender patients at the health system for years. That changed last Thursday when the hospital abruptly canceled all upcoming gender-affirming top surgeries—leaving patients in distress and without critical care they had already been approved for.
No amount of carefully crafted wording can erase the fact that these cancellations are a direct disruption of vital, medically necessary care for transgender individuals in our community. Memorial Health's statement does not explain why these procedures were suddenly halted, nor does it acknowledge the harm this decision inflicts on those who had already planned for surgery. We call on Memorial Health to reaffirm its commitment to equitable, patient-centered care for all members of our community, including transgender individuals. The Savannah Pride Center stands with those affected, and we will continue to advocate for their right to access the medical care they need and deserve.'
We reached out to Memorial Health about the decision, and they referred us to the statement above.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Magazine
33 minutes ago
- Time Magazine
Trump's First Surgeon General: RFK Jr. Purging the CDC Advisory Committee Will Put Lives at Risk
When Secretary Robert F. Kennedy Jr. began his tenure as Health and Human Services Secretary, he pledged, 'We won't take away anyone's vaccines.' However, recent policy changes under his leadership—coupled with the unprecedented dismissal of all 17 members of the CDC's Advisory Committee on Immunization Practices (ACIP) on June 9—have proven that statement false, raising grave concerns for our nation's COVID-19 response and broader vaccine policies. These shifts not only jeopardize public health but also threaten to erode trust in our health institutions at a critical time. In May 2025, the Food and Drug Administration (FDA) introduced a new COVID-19 vaccine framework, limiting access to updated vaccines for Americans aged 65 and older or those with specific risk factors. Furthermore, Secretary Kennedy announced that the Centers for Disease Control and Prevention (CDC) would no longer recommend COVID-19 vaccines for 'healthy' children or pregnant women—bypassing the standard ACIP review process. Compounding these changes, the abrupt removal of ACIP's entire panel of independent experts, who have guided evidence-based vaccine policy for decades, risks destabilizing a cornerstone of public health. These actions collectively restrict access to a vital tool for saving lives and undermine confidence in our health systems. During my tenure as Surgeon General under the first Trump administration, we faced significant public health challenges, from addressing the opioid epidemic by increasing access to Naloxone to launching Operation Warp Speed for the COVID-19 vaccine development effort. The vaccines developed under Trump's first term have proven to be one of our most effective defenses against COVID-19; yet, the current administration's new policies limit their availability, potentially leaving millions vulnerable. The dismissal of ACIP's experts—without a clear plan for replacing them with qualified scientists—further jeopardizes trust in the institutions tasked with protecting Americans. The major flaw in the new vaccine framework is its narrow assessment of risk. Although the immediate dangers of COVID-19 have lessened, it remains a leading cause of death and hospitalization, claiming nearly 50,000 lives in the U.S. in 2024—more than breast cancer or car accidents. The fact is, 75% of Americans have risk factors, such as obesity or diabetes, that increase their vulnerability to severe COVID outcomes. However, the burden is now placed on individuals to self-identify as high risk, creating confusion and inconsistency in access. Unlike other countries with centralized systems for identifying at-risk individuals, the U.S. expects patients—many of whom lack easy access to healthcare—to navigate eligibility alone. Risk assessment should also consider individual circumstances beyond underlying health conditions. A 58-year-old bus driver or healthcare worker faces significantly greater exposure than someone working remotely. By limiting vaccines to specific groups based solely on preexisting health status, the policy overlooks these critical contextual differences. Secretary Kennedy's team argues that there is insufficient evidence to support updated COVID-19 vaccines for healthy Americans under 65, but this claim is flatly unfounded. Years of real-world data demonstrate that vaccines save lives and reduce hospitalizations across all age groups. During the 2023 to 2024 fall and winter season, 95% of those hospitalized for COVID had not received an updated vaccine. While the administration cites other countries' more restrictive vaccine policies, such comparisons ignore the unique health landscape in the U.S., which includes higher obesity rates, worse maternal health outcomes, and uneven healthcare access. The policy also neglects the issue of Long COVID, which affects millions with debilitating symptoms lasting months or years. Though older adults are at higher risk for severe acute infections, Long COVID disproportionately impacts adults aged 35 to 49—and children are also affected. Vaccination reduces the risk of developing Long COVID, an essential reason many healthy individuals choose to stay up-to-date with their vaccines. Particularly concerning is the decision to end COVID vaccine recommendations for 'healthy' pregnant women, which contradicts the FDA's own guidance. Pregnant women face heightened risks of severe COVID outcomes, including death, pre-eclampsia, and miscarriage. Vaccination during pregnancy is crucial—not just for maternal health but also for protecting infants under six months, who cannot be vaccinated and rely on maternal antibodies for protection. Decades of research confirm that vaccines, including COVID vaccines, safely transfer antibodies to newborns, lowering their risk of severe illness. The dismissal of ACIP's members amplifies these concerns. ACIP has been a trusted, science-driven body that ensures vaccines are safe and effective, saving countless lives through its transparent recommendations. Its members, rigorously vetted for expertise and conflicts of interest, provide independent guidance critical to public health. Removing them without clear evidence of misconduct risks replacing qualified scientists with less experienced voices. This move fuels vaccine hesitancy and skepticism about public health decisions, particularly when paired with the bypassing of ACIP's review process for the new COVID vaccine policies. These changes create uncertainty about who can access vaccines. Without clear CDC recommendations, insurance companies may impose their own coverage criteria, potentially increasing costs for a vaccine that was previously free for most Americans. Healthcare providers, lacking federal guidance and ACIP's expertise, may struggle to advise patients, leading to a confusing and inequitable system that limits choice—hardly the 'medical freedom' Secretary Kennedy claims to champion. Ultimately, these actions threaten to erode trust in public health. FDA officials argue the new framework enhances transparency, yet bypassing ACIP's review and dismissing its members undermines that aim. Extensive data demonstrate that updated vaccines lower hospitalization and death rates, yet this evidence was sidelined. Such actions breed skepticism, making it harder to unite Americans around shared health goals. The stakes are high, but a better path is possible. Restoring trust requires transparent, evidence-based policymaking that prioritizes access to life-saving tools. I urge Secretary Kennedy and the administration to reconsider this framework, reinstate ACIP's role in vaccine policy, and ensure any new appointees are qualified, independent experts. If concerns about ACIP exist, they should be addressed through reform, not dissolution. Healthcare providers and community leaders must also educate patients about vaccination benefits, particularly for vulnerable groups like pregnant women and those with high exposure. Individuals can take action by staying informed, discussing vaccination with their doctors, and advocating for clear, equitable access to vaccines. By working together—government, providers, and citizens—we can protect lives, reduce the burden of Long COVID, and rebuild confidence in our public health system. We must seize this opportunity to unite around science and ensure a healthier, safer, and prosperous future for all Americans.
Politico
38 minutes ago
- Politico
Trump's research budget plan hits the ringer
WASHINGTON WATCH NIH Director Jay Bhattacharya offered a lukewarm defense of the 40 percent cut the Trump administration has proposed for his agency during testimony before a Senate Appropriations panel Tuesday. Asked to defend the administration's fiscal 2026 budget plan, which also calls for a major agency reorganization, Bhattacharya repeatedly demurred, saying 'the budget is a collaboration between Congress and the administration.' Bhattcharya also distanced himself from President Donald Trump's fight with universities and Elon Musk's Department of Government Efficiency, which led a cost-cutting campaign before Bhattacharya's March confirmation. Bhattacharya called that period — when the NIH proposed to cap the rates it pays university grantees to cover their administrative costs, laid off hundreds of probationary workers, and began an assault on universities Trump accuses of anti-semitism — 'a very bumpy time.' His testimony annoyed Democrats. In one representative exchange, Illinois' Dick Durbin asked Bhattacharya to take responsibility for Trump's move to freeze funding for Northwestern University, based in a Chicago suburb, leading to a tense back-and-forth. 'The buck stops in your office,' Durbin said. 'I know it does,' Bhattacharya responded. Why it matters: Bhattacharya is under fire from Democrats and many of his own employees for the cuts the administration has already made, which include about 2,500 jobs, and slowed grant funding that's reduced awards given out by $1.6 billion compared to last year. He's sought to reassure them that now that he's in charge further agency moves will be more carefully considered and that funding will again flow, though some of the grantees will be different. WELCOME TO FUTURE PULSE This is where we explore the ideas and innovators shaping health care. Doctors and their spouses go to the emergency room 20 percent less often than others, a Harvard study found. Why? Doctors can write their own prescriptions. Share any thoughts, news, tips and feedback with Danny Nguyen at dnguyen@ Carmen Paun at cpaun@ Ruth Reader at rreader@ or Erin Schumaker at eschumaker@ Want to share a tip securely? Message us on Signal: Dannyn516.70, CarmenP.82, RuthReader.02 or ErinSchumaker.01. WORLDVIEW GOP lawmakers are pushing back on President Donald Trump's proposed cuts to the President's Emergency Plan for AIDS Relief, our Meredith Lee Hill reports. It's one of the first signals that the Republicans who control Congress aren't happy with everything Trump's Department of Government Efficiency did and aren't likely to rubber stamp Trump's fiscal 2026 budget proposal. State of play: The disagreement over PEPFAR stems from Trump's request that Congress rescind $400 million in money it has already asked the administration to spend on global health programs. That includes some funding for the HIV and AIDS relief program. Then-President George W. Bush created PEPFAR in 2003 and it's since been credited with saving 25 million lives, mostly in Africa. In order to shore up support for the rescission package, White House officials have conveyed to GOP leaders that they will not only maintain life-saving treatments under PEPFAR but will also — in response to concerns from more than a dozen House Republicans — preserve some prevention programs as well, according to three people granted anonymity to discuss the private assurances. Speaker Mike Johnson's whip team conveyed the altered plans in conversations and text messages with lawmakers, our Meredith Lee Hill reports. Even so: White House budget director Russ Vought told appropriators last week that the Trump administration wants to take 'an analytical look' at 'the prevention itself' and instead fund 'life-saving treatment' for people with AIDS. But Vought said the White House is still planning to scale down PEPFAR and other programs. 'It is something that our budget will be very trim on,' Vought said of funding AIDS prevention work, 'because we believe that many of these nonprofits are not geared towards the viewpoints of the administration. And we're $37 trillion in debt. So at some point, the continent of Africa needs to absorb more of the burden of providing this health care.'
Yahoo
39 minutes ago
- Yahoo
Drug pricing reform talks with US government lack clarity, industry executives say
By Bhanvi Satija and Christy Santhosh (Reuters) -Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and how reduced prices will be implemented, top executives from Eli Lilly and Merck said at an industry conference on Tuesday. President Donald Trump issued an executive order last month directing drugmakers to lower the prices of their medicines to align with what other countries pay. According to the order, the administration was to set "most favored nation" price targets within 30 days. The Department of Health and Human Services has said it expects drugmakers in the U.S. to set prices for their products at the lowest price paid by other high-income countries. Lilly's chief financial officer, Lucas Montarce, said that it was not clear when a resolution on the pricing reform would be achieved. "It's hard to make any assumption about when, but they haven't shared with us any details at this time," said Montarce at the Goldman Sachs' Healthcare Conference. On Monday, Pfizer's chief executive Albert Bourla had said that the meetings with the Trump administration were focused on high-level ideas and not "digging into the substance." "Conversations are ongoing. No clarity yet on where it's going to go," said Merck's CEO Robert Davis. Davis added that Merck has discussed how to share the cost of drug innovation, both in the United States and other countries, with the administration. "But how does that all translate into an actionable plan in the near term? There's still a lot of dialog happening, so that's not as clear," he said. Lilly and Merck executives said that any pricing reforms would require regulatory changes or government-to-government actions. AbbVie's CEO also said that there was a "long way to go" before an agreement would be reached on the pricing reform. Sign in to access your portfolio
